Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
H.J. Schunemann, D. Best, G. Vist, A.D. Oxman.
Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations.
CMAJ, 169 (2003), pp. 677-680
[2.]
J. Ferlay, F. Bray, P. Pisani, D.M. Parkin.
GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, 10.a ed.
[3.]
Mortalidad por cáncer y otras causas en España, año 2000 Centro Nacional de Epidemiología, 2000 En: http://193.146.50.130/cancer/cancer1.htm
[4.]
S.J. Winawer, R.H. Fletcher, L. Miller, F. Godlee, M.H. Stolar, C.D. Mulrow, et al.
Colorectal cancer screening: clinical guidelines and rationale.
Gastroenterology, 112 (1997), pp. 594-642
[5.]
Piñol V, Andreu M, Castells A, Payá A, Bessa X, Jover R. Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain. A multicenter, prospective, nation-wide study. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Eur J Gastroenterol Hepatol [en prensa]
[6.]
G. Gatta, R. Capocaccia, M.P. Coleman, L.A. Gloeckler Ries, T. Hakulinen, A. Micheli, et al.
Toward a comparison of survival in American and European cancer patients.
Cancer, 89 (2000), pp. 893-900
[7.]
D.A. Ahlquist, T.M. Pasha.
Clinical aspects of sporadic colorectal cancer.
Gastrointestinal cancers, pp. 379-405
[8.]
E. Giovannucci.
Modifiable risk factors for colon cancer.
Gastroenterol Clin North Am, 31 (2002), pp. 925-943
[9.]
E. Giovannucci, B. Goldin.
The role of fat fatty acids, and total energy intake in the etiology of human colon cancer.
Am J Clin Nutr, 66 (1997), pp. 1.564S-1.571S
[10.]
T. Norat, E. Riboli.
Dairy products and colorectal cancer. A review of possible mechanisms and epidemiological evidence.
Eur J Clin Nutr, 57 (2003), pp. 1-17
[11.]
M.S. Sandhu, I.R. White, K. McPherson.
Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach.
Cancer Epidemiol Biomarkers Prev, 10 (2001), pp. 439-446
[12.]
T. Norat, A. Lukanova, P. Ferrari, E. Riboli.
Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies.
Int J Cancer, 98 (2002), pp. 241-256
[13.]
T. Norat, A. Lukanova, P. Ferrari, E. Riboli.
Meat consumption and colorectal cancer risk: an estimate of attributable and preventable fractions.
IARC Sci Publ, 156 (2002), pp. 223-225
[14.]
L. Le Marchand.
Meat intake, metabolic genes and colorectal cancer.
IARC Sci Publ, 156 (2002), pp. 481-485
[15.]
E. Riboli, T. Norat.
Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk.
Am J Clin Nutr, 78 (2003), pp. 559S-569S
[16.]
S.A. Bingham, N.E. Day, R. Luben, P. Ferrari, N. Slimani, T. Norat, et al.
Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study.
Lancet, 361 (2003), pp. 1.496-1.501
[17.]
K.B. Michels, G. Edward, K.J. Joshipura, B.A. Rosner, M.J. Stampfer, C.S. Fuchs, et al.
Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers.
J Natl Cancer Inst, 92 (2000), pp. 1.740-1.752
[18.]
T. Asano, R. McLeod.
Dietary fibre for the prevention of colorectal adenomas and carcinomas (Cochrane Review). En: The Cochrane Library.
[19.]
U. Peters, R. Sinha, N. Chatterjee, A.F. Subar, R.G. Ziegler, M. Kulldorff, et al.
Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme.
Lancet, 361 (2003), pp. 1.491-1.495
[20.]
M.E. Martinez, W.C.Calcium Willett, D. vitamin.
and colorectal cancer: a review of the epidemiologic evidence.
Cancer Epidemiol Biomarkers Prev, 7 (1998), pp. 163-168
[21.]
K. Wu, W.C. Willett, C.S. Fuchs, G.A. Colditz, E.L. Giovannucci.
Calcium intake and risk of colon cancer in women and men.
J Natl Cancer Inst, 94 (2002), pp. 437-446
[22.]
B. Hofstad, K. Almendingen, M. Vatn, S.N. Andersen, R.W. Owen, S. Larsen, et al.
Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and anti-oxidants.
Digestion, 59 (1998), pp. 148-156
[23.]
J.A. Baron, M. Beach, J.S. Mandel, R.U. van Stolk, R.W. Haile, R.S. Sandler, et al.
Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group.
N Engl J Med, 340 (1999), pp. 101-107
[24.]
C. Bonithon-Kopp, O. Kronborg, A. Giacosa, U. Rath, J. Faivre.
Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group.
Lancet, 356 (2000), pp. 1.300-1.306
[25.]
I.M. Lee, N.R. Cook, J.E. Manson, J.E. Buring, C.H. Hennekens.
Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study.
J Natl Cancer Inst, 91 (1999), pp. 2.102-2.106
[26.]
N.R. Cook, I.M. Le, J.E. Manson, J.E. Buring, C.H. Hennekens.
Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States).
Cancer Causes Control, 11 (2000), pp. 617-626
[27.]
N. Malila, J. Virtamo, M. Virtanen, P. Pietinen, D. Albanes, L. Teppo.
Dietary and serum alpha-tocopherol, beta-carotene and retinol, and risk for colorectal cancer in male smokers.
Eur J Clin Nutr, 56 (2002), pp. 615-621
[28.]
Ritenbaugh C, Streit K, Helfand M. Routine supplementation to prevent cancer: a summary of the evidence from randomized controlled trials for the U.S. Preventive Task Force. En: http://www.ahcpr.gov/clinic/3rduspstf/vitamins/vitasum.htm
[29.]
E.R. Greenberg, J.A. Baron, T.D. Tosteson, D.H. Freeman Jr, G.J. Beck, J.H. Bond, et al.
A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group.
N Engl J Med, 331 (1994), pp. 141-147
[30.]
R. MacLennan, F. Macrae, C. Bain, D. Battistutta, P. Chapuis, H. Gratten, et al.
Randomized trial of intake of fat fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project.
J Natl Cancer Inst, 87 (1995), pp. 1.760-1.766
[31.]
J.A. Baron, B.F. Cole, L. Mott, R. Haile, M. Grau, T.R. Church, et al.
Neoplastic and Antineoplastic Effects of beta-Carotene on Colorectal Adenoma Recurrence: Results of a Randomized Trial.
J Natl Cancer Inst, 95 (2003), pp. 717-722
[32.]
A.J. Duffield-Lillico, M.E. Reid, B.W. Turnbull, G.F. Combs Jr, E.H. Slate, L.A. Fischbach, et al.
Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial.
Cancer Epidemiol Biomarkers Prev, 11 (2002), pp. 630-639
[33.]
IARC Working Group on the Evaluation of Cancer-Preventive Agents.
Weight control and physical activity. Handbooks of cancer prevention, vol. 6.
[34.]
V. Bagnardi, M. Blangiardo, C. La Vecchia, G. Corrao.
A metaanalysis of alcohol drinking and cancer risk.
Br J Cancer, 85 (2001), pp. 1.700-1.705
[35.]
E. Giovannucci.
An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer.
Cancer Epidemiol Biomarkers Prev, 10 (2001), pp. 725-731
[36.]
H. Kuper, P. Boffetta, H.O. Adami.
Tobacco use and cancer causation: association by tumour type.
J Intern Med, 252 (2002), pp. 206-224
[37.]
L.A. Garcia-Rodriguez, C. Huerta-Alvarez.
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.
Epidemiology, 12 (2001), pp. 88-93
[38.]
IARC Working Group on the Evaluation of Cancer Preventive Agents.
Non-steroidal anti-inflammatory drugs.
[39.]
D. Gatof, D. Ahnen.
Primary prevention of colorectal cancer: diet and drugs.
Gastroenterol Clin North Am, 31 (2002), pp. 587-623
[40.]
N. Vaisman, N. Arber.
The role of nutrition and chemoprevention in colorectal cancer: from observations to expectations.
Best Pract Res Clin Gastroenterol, 16 (2002), pp. 201-217
[41.]
P.H. Gann, J.E. Manson, R.J. Glynn, J.E. Buring, C.H. Hennekens.
Low-dose aspirin and incidence of colorectal tumors in a randomized trial.
J Natl Cancer Inst, 85 (1993), pp. 1.220-1.224
[42.]
T. Sturmer, R.J. Glynn, I.M. Lee, J.E. Manson, J.E. Buring, C.H. Hennekens.
Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study.
Ann Intern Med, 128 (1998), pp. 713-720
[43.]
J.A. Baron, B.F. Cole, R.S. Sandler, R.W. Haile, D. Ahnen, R. Bresalier, et al.
A randomized trial of aspirin to prevent colorectal adenomas.
N Engl J Med, 348 (2003), pp. 891-899
[44.]
N. Hebert-Croteau.
A meta-analysis of hormone replacement therapy and colon cancer in women.
Cancer Epidemiol Biomarkers Prev, 7 (1998), pp. 653-659
[45.]
K. Nanda, L.A. Bastian, V. Hasselblad, D.L. Simel.
Hormone replacement therapy and the risk of colorectal cancer: a metaanalysis.
Obstet Gynecol, 93 (1999), pp. 880-888
[46.]
V. Beral, E. Banks, G. Reeves, P. Appleby.
Use of HRT and the subsequent risk of cancer.
J Epidemiol Biostat, 4 (1999), pp. 191-210
[47.]
F. Grodstein, P.A. Newcomb, M.J. Stampfer.
Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis.
Am J Med, 106 (1999), pp. 574-582
[48.]
J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, et al.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
JAMA, 288 (2002), pp. 321-333
[49.]
S. Hulley, C. Furberg, E. Barrett-Connor, J. Cauley, D. Grady, W. Haskell, et al.
Noncardio-vascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
JAMA, 288 (2002), pp. 58-66
[50.]
Grupo de trabajo de la guía de práctica clínica sobre rectorragia. Manejo del paciente con rectorragia. Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2002 Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 2
[51.]
A.J. Stellon, S.E. Kenwright.
Iron deficiency anaemia in general practice: presentations and investigations.
Br J Clin Pract, 51 (1997), pp. 78-80
[52.]
M. Helfand, K.I. Marton, M.J. Zimmer-Gembeck, H.C. Sox Jr.
History of visible rectal bleeding in a primary care population. Initial assessment and 10-year follow-up.
JAMA, 277 (1997), pp. 44-48
[53.]
Scottish Intercollegiate Guidelines Network (SIGN). Management of colorectal cancer, 2003 En: http://www.sign.ac.uk/pdf/sign67.pdf
[54.]
S. Winawer, R. Fletcher, D. Rex, J. Bond, R. Burt, J. Ferrucci, et al.
Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.
Gastroenterology, 124 (2003), pp. 544-560
[55.]
M. Marzo.
Diagnóstico rápido de cáncer.
Cuadernos de Gestión, (2002), pp. 25-36
[56.]
The NHS Plan. A plan for investment. A plan for reform. Department of Health; 2000 En: http://www.doh.gov.uk/nhsplan/nhsplan.pdf
[57.]
A. Crosland, R. Jones.
Rectal bleeding: prevalence and consultation behaviour.
BMJ, 311 (1995), pp. 486-488
[58.]
V. Mor, S. Masterson-Allen, R. Goldberg, E. Guadagnoli, M.S. Wool.
Pre-diagnostic symptom recognition and help seeking among cancer patients.
J Community Health, 15 (1990), pp. 253-266
[59.]
H.W. Holliday, J.D. Hardcastle.
Delay in diagnosis and treatment of symptomatic colorectal cancer.
Lancet, 1 (1979), pp. 309-311
[60.]
E. Fernandez, M. Porta, N. Malats, J. Belloc, M. Gallen.
Symptom-to-diagnosis interval and survival in cancers of the digestive tract.
Dig Dis Sci, 47 (2002), pp. 2.434-2.440
[61.]
D. Goodman, T.T. Irvin.
Delay in the diagnosis and prognosis of carcinoma of the right colon.
Br J Surg, 80 (1993), pp. 1.327-1.329
[62.]
M.A. Potter, R.G. Wilson.
Diagnostic delay in colorectal cancer.
J R Coll Surg Edinb, 44 (1999), pp. 313-316
[63.]
J. Mansson, B. Marklun, R. Hultborn.
The diagnosis of cancer in the “roar™ of potential cancer symptoms of patients in primary health care. Research by means of the computerised journal.
Scand J Prim Health Care, 19 (2001), pp. 83-89
[64.]
D.F. Ransohoff, C.A. Lang.
Screening for colorectal cancer.
N Engl J Med, 325 (1991), pp. 37-41
[65.]
D.K. Rex, D.A. Johnson, D.A. Lieberman, R.W. Burt, A. Sonnenberg.
Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. American College of Gastroenterology.
Am J Gastroenterol, 95 (2000), pp. 868-877
[66.]
J.M. Rhodes.
Colorectal cancer screening in the UK: Joint Position Statement by the British Society of Gastroenterology, The Royal College of Physicians, and The Association of Coloproctology of Great Britain and Ireland.
Gut, 46 (2000), pp. 746-748
[68.]
R.A. Smith, A.C. von Eschenbach, R. Wender, B. Levin, T. Byers, D. Rothenberger, et al.
American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection.
CA Cancer J Clin, 51 (2001), pp. 38-75
[69.]
Colorectal cancer screening.
Recommendation statement from the Canadian Task Force on Preventive Health Care.
CMAJ, 165 (2001), pp. 206-208
[70.]
R.A. Smith, V. Cokkinides, A.C. von Eschenbach, B. Levin, C. Cohen, C.D. Runowicz, et al.
American Cancer Society guidelines for the early detection of cancer.
CA Cancer J Clin, 52 (2002), pp. 8-22
[71.]
Screening for colorectal cancer: recommendation and rationale.
Ann Intern Med, 137 (2002), pp. 129-131
[72.]
M. Pignone, M. Rich, S.M. Teutsch, A.O. Berg, K.N. Lohr.
Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force.
Ann Intern Med, 137 (2002), pp. 132-141
[73.]
Screening for colorectal cancer in adults systematic evidence review. Agency for Healthcare Research and Quality, 2002 En: http://www.ahcpr.gov/clinic/uspstf/uspscolo.htm
[74.]
J.M. Walsh, J.P. Terdiman.
Colorectal cancer screening: clinical applications.
JAMA, 289 (2003), pp. 1.297-1.302
[75.]
J.M. Walsh, J.P. Terdiman.
Colorectal cancer screening: scientific review.
JAMA, 289 (2003), pp. 1.288-1.296
[76.]
R.A. Smith, V. Cokkinides, H.J. Eyre.
American Cancer Society guidelines for the early detection of cancer, 2003.
CA Cancer J Clin, 53 (2003), pp. 27-43
[77.]
J.H. Scholefield, S. Moss, F. Sufi, C.M. Mangham, J.D. Hardcastle.
Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial.
Gut, 50 (2002), pp. 840-844
[78.]
J.S. Mandel, J.H. Bond, T.R. Church, D.C. Snover, G.M. Bradley, L.M. Schuman, et al.
Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.
N Engl J Med, 328 (1993), pp. 1.365-1.371
[79.]
J.D. Hardcastle, J.O. Chamberlain, M.H. Robinson, S.M. Moss, S.S. Amar, T.W. Balfour, et al.
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.
Lancet, 348 (1996), pp. 1.472-1.477
[80.]
O. Kronborg, C. Fenger, J. Olsen, O.D. Jorgensen, O. Sondergaard.
Randomised study of screening for colorectal cancer with faecal-occult-blood test.
Lancet, 348 (1996), pp. 1.467-1.471
[81.]
B. Towler, L. Irwig, P. Glasziou, D. Weller, J. Kewenter.
Screening for colorectal cancer using the faecal occult blood test, hemoccult.
Cochrane Database Systematic Review, 2 (2000), pp. CD001216
[82.]
J.H. Scholefield, S.M. Moss.
Faecal occult blood screening for colorectal cancer.
J Med Screen, 9 (2002), pp. 54-55
[83.]
J.S. Mandel, T.R. Church, F. Ederer, J.H. Bond.
Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
J Natl Cancer Inst, 91 (1999), pp. 434-437
[84.]
J.S. Mandel, T.R. Church, J.H. Bond, F. Ederer, M.S. Geisser, S.J. Mongin, et al.
The effect of fecal occult-blood screening on the incidence of colorectal cancer.
N Engl J Med, 343 (2000), pp. 1.603-1.607
[85.]
E.J. Bini, R.C. Rajapaksa, E.H. Weinshel.
The findings and impact of nonrehydrated guaiac examination of the rectum (FINGER) study: a comparison of 2 methods of screening for colorectal cancer in asymptomatic average-risk patients.
Arch Intern Med, 159 (1999), pp. 2.022-2.026
[86.]
M.S. Eisner, J.H. Lewis.
Diagnostic yield of a positive fecal occult blood test found on digital rectal examination. Does the finger count?.
Arch Intern Med, 151 (1991), pp. 2.180-2.184
[87.]
J.V. Selby, G.D. Friedman, J.r. Quesenberry CP, N.S. Weiss.
A case-control study of screening sigmoidoscopy and mortality from colorectal cancer.
N Engl J Med, 326 (1992), pp. 653-657
[88.]
P.A. Newcomb, R.G. Norfleet, B.E. Storer, T.S. Surawicz, P.M. Marcus.
Screening sigmoidoscopy and colorectal cancer mortality.
J Natl Cancer Inst, 84 (1992), pp. 1.572-1.575
[89.]
P.A. Newcomb, B.E. Storer, L.M. Morimoto, A. Templeton, J.D. Potter.
Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence.
J Natl Cancer Inst, 95 (2003), pp. 622-625
[90.]
E. Thiis-Evensen, G.S. Hoff, J. Sauar, F. Langmark, B.M. Majak, M.H. Vatn.
Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I.
Scand J Gastroenterol, 34 (1999), pp. 414-420
[91.]
Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial.
Lancet, 359 (2002), pp. 1.291-1.300
[92.]
N. Segnan, C. Senore, B. Andreoni, H. Aste, L. Bonelli, C. Crosta, et al.
Baseline findings of the Italian multicenter randomized controlled trial of “once-only sigmoidoscopy™-SCORE.
J Natl Cancer Inst, 94 (2002), pp. 1.763-1.772
[93.]
B.S. Kramer, J. Gohagan, P.C. Prorok, C. Smart.
A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
Cancer, 71 (1993), pp. 589-593
[94.]
W.S. Atkin, A. Hart, R. Edwards, P. McIntyre, R. Aubrey, J. Wardle, et al.
Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening.
Gut, 42 (1998), pp. 560-565
[95.]
D.A. Lieberman, D.G. Weiss, J.H. Bond, D.J. Ahnen, H. Garewal, G. Chejfec.
Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380.
N Engl J Med, 343 (2000), pp. 162-168
[96.]
T.F. Imperiale, D.R. Wagner, C.Y. Lin, G.N. Larkin, J.D. Rogge, D.F. Ransohoff.
Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings.
N Engl J Med, 343 (2000), pp. 169-174
[97.]
J.D. Lewis, K. Ng, K.E. Hung, W.B. Bilker, J.A. Berlin, C. Brensinger, et al.
Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy.
Arch Intern Med, 163 (2003), pp. 413-420
[98.]
P. Schoenfeld, S. Lipscomb, J. Crook, J. Dominguez, J. Butler, L. Holmes, et al.
Accuracy of polyp detection by gastroenterologists and nurse endoscopists during flexible sigmoidoscopy: a randomized trial.
Gastroenterology, 117 (1999), pp. 312-318
[99.]
P.C. Schroy, T. Heeren, C.M. Bliss, J. Pincus, S. Wilson, M. Prout.
Implementation of on-site screening sigmoidoscopy positively influences utilization by primary care providers.
Gastroenterology, 117 (1999), pp. 304-311
[100.]
D.A. Macafee, J.H. Scholefield.
Antagonist: population based endoscopic screening for colorectal cancer.
Gut, 52 (2003), pp. 323-326
[101.]
S.J. Winawer, B.J. Flehinger, D. Schottenfeld, D.G. Miller.
Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy.
J Natl Cancer Inst, 85 (1993), pp. 1.311-1.318
[102.]
J.E. Verne, R. Aubrey, S.B. Love, I.C. Talbot, J.M. Northover.
Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing.
BMJ, 317 (1998), pp. 182-185
[103.]
S.M. Scheitel, D.A. Ahlquist, P.C. Wollan, P.T. Hagen, M.D. Silverstein.
Colorectal cancer screening: a community case-control study of proctosigmoidoscopy, barium enema radiography, and fecal occult blood test efficacy.
Mayo Clin Proc, 74 (1999), pp. 1.207-1.213
[104.]
S.J. Winawer, E.T. Stewart, A.G. Zauber, J.H. Bond, H. Ansel, J.D. Waye, et al.
A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group.
N Engl J Med, 342 (2000), pp. 1.766-1.772
[105.]
S.J. Winawer, A.G. Zauber, T. Church, M. Mandelson, A. Feld, J. Bond, et al.
National Colonoscopy Study (NCS) preliminary results: a randomized controlled trial of general population screening colonoscopy.
Gastroenterology, 122 (2002), pp. A480
[106.]
A.D. Muller, A. Sonnenberg.
Protection by endoscopy against death from colorectal cancer. A case-control study among veterans.
Arch Intern Med, 155 (1995), pp. 1.741-1.748
[107.]
A.L. Frazier, G.A. Colditz, C.S. Fuchs, K.M. Kuntz.
Cost-effectiveness of screening for colorectal cancer in the general population.
JAMA, 284 (2000), pp. 1.954-1.961
[108.]
S.J. Winawer, A.G. Zauber, M.J. O'Brien, M.N. Ho, L. Gottlieb, S.S. Sternberg, et al.
Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup.
N Engl J Med, 328 (1993), pp. 901-906
[109.]
F. Citarda, G. Tomaselli, R. Capocaccia, S. Barcherini, M. Crespi.
Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence.
Gut, 48 (2001), pp. 812-815
[110.]
D.K. Rex, O.W. Cummings, D.J. Helper, T.V. Nowak, J.M. McGill, G.Z. Chiao, et al.
5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons.
Gastroenterology, 111 (1996), pp. 1.178-1.181
[111.]
D.K. Rex, C.S. Cutler, G.T. Lemmel, E.Y. Rahmani, D.W. Clark, D.J. Helper, et al.
Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies.
Gastroenterology, 112 (1997), pp. 24-28
[112.]
J.H. Haseman, G.T. Lemmel, E.Y. Rahmani, D.K. Rex.
Failure of colonoscopy to detect colorectal cancer: evaluation of 47 cases in 20 hospitals.
Gastrointest Endosc, 45 (1997), pp. 451-455
[113.]
B.J. Rembacken, T. Fujii, A. Cairns, M.F. Dixon, S. Yoshida, D.M. Chalmers, et al.
Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the U.K.
Lancet, 355 (2000), pp. 1.211-1.214
[114.]
J.C. Brooker, B.P. Saunders, S.G. Shah, C.J. Thapar, H.J. Thomas, W.S. Atkin, et al.
Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial.
Gastrointest Endosc, 56 (2002), pp. 333-338
[115.]
M.G. Dunlop.
Guidance on large bowel surveillance for people with two first degree relatives with colorectal cancer or one first degree relative diagnosed with colorectal cancer under 45 years.
Gut, 51 (2002), pp. V17-V20
[116.]
P.J. Pickhardt, J.R. Choi, I. Hwang, J.A. Butler, M.L. Puckett, H.A. Hildebrandt, et al.
Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults.
N Engl J Med, 349 (2003), pp. 2.191-2.200
[117.]
M. Pignone, S. Saha, T. Hoerger, J. Mandelblatt.
Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force.
Ann Intern Med, 137 (2002), pp. 96-104
[118.]
J. Wardle, T. Taylor, S. Sutton, W. Atkin.
Does publicity about cancer screening raise fear of cancer? Randomised trial of the psychological effect of information about cancer screening.
BMJ, 319 (1999), pp. 1.037-1.038
[119.]
E.G. Stone, S.C. Morton, M.E. Hulscher, M.A. Maglione, E.A. Roth, J.M. Grimshaw, et al.
Interventions that increase use of adult immunization and cancer screening services: a meta-analysis.
Ann Intern Med, 136 (2002), pp. 641-651
[120.]
A. Edwards, S. Unigwe, G. Elwyn, K. Hood.
Effects of communicating individual risks in screening programmes: Cochrane systematic review.
BMJ, 327 (2003), pp. 703-709
[121.]
Propuesta de Recomendación del Consejo sobre cribado del cáncer. Comisión de las Comunidades Europeas, 2003 En: http://www.who.int/cancer/nccp/en/ecproposalforcouncilrecommendationes.pdf
[122.]
Plan Integral del Cáncer. Detección precoz. Dirección General Agencia de Calidad, 2003 (Borrador en fase de revisión)
[123.]
P. Tarraga, D. Garcia-Olmo, A. Celada, M. Garcia-Molinero, J.A. Divison, C. Casado.
Colorectal cancer screening through detection of fecal occult blood in a controlled health zone.
Rev Esp Enferm Dig, 91 (1999), pp. 335-344
[124.]
Servicio de Prevención y Control del Cáncer. Programa piloto cribado del cáncer colorrectal en Hospitalet de Llobregat, periodo 2000-2002 Informe resultados primera ronda de cribado.
Institut Català d'Oncologia, (2002),
[125.]
A.K. Rustgi.
Hereditary gastrointestinal polyposis and nonpolyposis syndromes.
N Engl J Med, 331 (1994), pp. 1.694-1.702
[126.]
M.G. Dunlop.
Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome.
Gut, 51 (2002), pp. V21-V27
[127.]
D.T. Bishop, N.R. Hall.
The genetics of colorectal cancer.
Eur J Cancer, 30A (1994), pp. 1.946-1.956
[128.]
H.T. Lynch, T. Smyrk, T. McGinn, S. Lanspa, J. Cavalieri, J. Lynch, et al.
Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP.
Cancer, 76 (1995), pp. 2.427-2.433
[129.]
F.M. Giardiello, J.D. Brensinger, M.C. Luce, G.M. Petersen, M.C. Cayouette, A.J. Krush, et al.
Phenotypic expression of disease in families that have mutations in the 5' region of the adenomatous polyposis coli gene.
Ann Intern Med, 126 (1997), pp. 514-519
[130.]
J.D. Brensinger, S.J. Laken, M.C. Luce, S.M. Powell, G.H. Vance, D.J. Ahnen, et al.
Variable phenotype of familial adenomatous polyposis in pedigrees with 3' mutation in the APC gene.
Gut, 43 (1998), pp. 548-552
[131.]
R.J. Gardner, D. Kool, E. Edkins, I.R. Walpole, F.A. Macrae, S. Nasioulas, et al.
The clinical correlates of a 3' truncating mutation (codons 1982-1983) in the adenomatous polyposis coli gene.
Gastroenterology, 113 (1997), pp. 326-331
[132.]
C. Soravia, T. Berk, L. Madlensky, A. Mitri, H. Cheng, S. Gallinger, et al.
Genotype-phenotype correlations in attenuated adenomatous polyposis coli.
Am J Hum Genet, 62 (1998), pp. 1.290-1.301
[133.]
F.M. Giardiello, J.D. Brensinger, G.M. Petersen.
AGA technical review on hereditary colorectal cancer and genetic testing.
Gastroenterology, 121 (2001), pp. 198-213
[134.]
W.M. Grady.
Genetic testing for high-risk colon cancer patients.
Gastroenterology, 124 (2003), pp. 1.574-1.594
[135.]
S.R. Hamilton, B. Liu, R.E. Parsons, N. Papadopoulos, J. Jen, S.M. Powell, et al.
The molecular basis of Turcot's syndrome.
N Engl J Med, 332 (1995), pp. 839-847
[136.]
D. Barel, I.J. Cohen, C. Mor, S. Stern, R. Shapiro, R. Shomrat, et al.
Mutations of the adenomatous polyposis coli and p53 genes in a child with Turcot's syndrome.
Cancer Lett, 132 (1998), pp. 119-125
[137.]
J. Groden, A. Thliveris, W. Samowitz, M. Carlson, L. Gelbert, H. Albertsen, et al.
Identification and characterization of the familial adenomatous polyposis coli gene.
Cell, 66 (1991), pp. 589-600
[138.]
H.J. Jarvinen.
Genetic testing for polyposis: practical and ethical aspects.
Gut, 52 (2003), pp. 19ii-22
[139.]
American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing.
Gastroenterology, 121 (2001), pp. 195-197
[140.]
P. Laurent-Puig, C. Beroud, T. Soussi.
APC gene: database of germline and somatic mutations in human tumors and cell lines.
Nucleic Acids Res, 26 (1998), pp. 269-270
[141.]
Y. Chikhaoui, H. Gelinas, L. Joseph, J.M. Lance.
Cost-minimization analysis of genetic testing versus clinical screening of atrisk relatives for familial adenomatous polyposis.
Int J Technol Assess Health Care, 18 (2002), pp. 67-80
[142.]
F.M. Giardiello, J.D. Brensinger, G.M. Petersen, M.C. Luce, L.M. Hylind, J.A. Bacon, et al.
The use and interpretation of commercial APC gene testing for familial adenomatous polyposis.
N Engl J Med, 336 (1997), pp. 823-827
[143.]
S. Bulow.
Results of national registration of familial adenomatous polyposis.
Gut, 52 (2003), pp. 742-746
[144.]
T. Berk, Z. Cohen, B. Bapat, S. Gallinger.
Negative genetic test result in familial adenomatous polyposis: clinical screening implications.
Dis Colon Rectum, 42 (1999), pp. 307-310
[145.]
Genetic testing for colon cancer: joint statement of the American College of Medical Genetics and American Society of Human Genetics. Joint Test and Technology Transfer Committee Working Group.
Genet Med, 2 (2000), pp. 362-366
[146.]
G.J. Offerhaus, F.M. Giardiello, A.J. Krush, S.V. Booker, A.C. Tersmette, N.C. Kelley, et al.
The risk of upper gastrointestinal cancer in familial adenomatous polyposis.
Gastroenterology, 102 (1992), pp. 1.980-1.982
[147.]
G. Griffioen, P.J. Bus, H.F. Vasen, H.W. Verspaget, C.B. Lamers.
Extracolonic manifestations of familial adenomatous polyposis: desmoid tumours, and upper gastrointestinal adenomas and carcinomas.
Scand J Gastroenterol Suppl, 225 (1998), pp. 85-91
[148.]
H.F. Vasen, S. Bulow, T. Myrhoj, L. Mathus-Vliegen, G. Griffioen, E. Buskens, et al.
Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis.
Gut, 40 (1997), pp. 716-719
[149.]
J. Bjork, H. Akerbrant, L. Iselius, A. Bergman, Y. Engwall, J. Wahlstrom, et al.
Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations.
Gastroenterology, 121 (2001), pp. 1.127-1.135
[150.]
D.L. Cahen, P. Fockens, L.T. de Wit, G.J. Offerhaus, H. Obertop, D.J. Gouma.
Local resection or pancreaticoduodenectomy for villous adenoma of the ampulla of Vater diagnosed before operation.
Br J Surg, 84 (1997), pp. 948-951
[151.]
C.J. Groves, B.P. Saunders, A.D. Spigelman, R.K. Phillips.
Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study.
Gut, 50 (2002), pp. 636-641
[152.]
C. Burke.
Risk stratification for periampullary carcinoma in patients with familial adenomatous polyposis: does theodore know what to do now?.
Gastroenterology, 121 (2001), pp. 1.246-1.248
[153.]
A. Pikaar, J.W. Nortier, G. Griffioen, H.F. Vasen.
[Desmoid tumors in patients with familial adenomatous polyposis].
Ned Tijdschr Geneeskd, 146 (2002), pp. 1.355-1.359
[154.]
H.T. Lynch, A. de la Chapelle.
Hereditary colorectal cancer.
N Engl J Med, 348 (2003), pp. 919-932
[155.]
F.M. Giardiello, G.J. Offerhaus, A.J. Krush, S.V. Booker, A.C. Tersmette, J.W. Mulder, et al.
Risk of hepatoblastoma in familial adenomatous polyposis.
J Pediatr, 119 (1991), pp. 766-768
[156.]
F.M. Giardiello, G.M. Petersen, J.D. Brensinger, M.C. Luce, M.C. Cayouette, J. Bacon, et al.
Hepatoblastoma and APC gene mutation in familial adenomatous polyposis.
Gut, 39 (1996), pp. 867-869
[157.]
M. Rhodes, D.M. Bradburn.
Overview of screening and management of familial adenomatous polyposis.
Gut, 33 (1992), pp. 125-131
[158.]
K.P. Nugent, JMA. Northover.
Total colectomy and ileorectal anastomosis.
Familial adenomatous polyposis, pp. 79-91
[159.]
H.F. Vasen, R.B. van der Luijt, J.F. Slors, E. Buskens, P. de Ruiter, C.G. Baeten, et al.
Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis.
Lancet, 348 (1996), pp. 433-435
[160.]
C. Bulow, H. Vasen, H. Jarvinen, J. Bjork, M.L. Bisgaard, S. Bulow.
Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis.
Gastroenterology, 119 (2000), pp. 1.454-1.460
[161.]
W. Friedl, R. Caspari, M. Sengteller, S. Uhlhaas, C. Lamberti, M. Jungck, et al.
Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families.
Gut, 48 (2001), pp. 515-521
[162.]
F.M. Giardiello, S.R. Hamilton, A.J. Krush, S. Piantadosi, L.M. Hylind, P. Celano, et al.
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
N Engl J Med, 328 (1993), pp. 1.313-1.316
[163.]
D. Labayle, D. Fischer, P. Vielh, F. Drouhin, A. Pariente, C. Bories, et al.
Sulindac causes regression of rectal polyps in familial adenomatous polyposis.
Gastroenterology, 101 (1991), pp. 635-639
[164.]
K.P. Nugent, K.C. Farmer, A.D. Spigelman, C.B. Williams, R.K. Phillips.
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
Br J Surg, 80 (1993), pp. 1.618-1.619
[165.]
G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, G.B. Gordon, et al.
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
N Engl J Med, 342 (2000), pp. 1.946-1.952
[166.]
P.A. Janne, R.J. Mayer.
Chemoprevention of colorectal cancer.
N Engl J Med, 342 (2000), pp. 1.960-1.968
[167.]
G. Huls, J.J. Koornstra, J.H. Kleibeuker.
Non-steroidal antiinflammatory drugs and molecular carcinogenesis of colorectal carcinomas.
Lancet, 362 (2003), pp. 230-232
[168.]
Y. Niv, G.M. Fraser.
Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy.
Gastroenterology, 107 (1994), pp. 854-857
[169.]
M. Cruz-Correa, L.M. Hylind, K.E. Romans, S.V. Booker, F.M. Giardiello.
Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
Gastroenterology, 122 (2002), pp. 641-645
[170.]
H.S. Debinski, J. Trojan, K.P. Nugent, A.D. Spigelman, R.K. Phillips.
Effect of sulindac on small polyps in familial adenomatous polyposis.
Lancet, 345 (1995), pp. 855-856
[171.]
R.K. Phillips, M.H. Wallace, P.M. Lynch, E. Hawk, G.B. Gordon, B.P. Saunders, et al.
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Gut, 50 (2002), pp. 857-860
[172.]
F.M. Giardiello, V.W. Yang, L.M. Hylind, A.J. Krush, G.M. Petersen, J.D. Trimbath, et al.
Primary chemoprevention of familial adenomatous polyposis with sulindac.
N Engl J Med, 346 (2002), pp. 1.054-1.059
[173.]
D.C. Chung, A.K. Rustgi.
The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications.
Ann Intern Med, 138 (2003), pp. 560-570
[174.]
W.S. Samowitz, K. Curtin, H.H. Lin, M.A. Robertson, D. Schaffer, M. Nichols, et al.
The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer.
Gastroentero-logy, 121 (2001), pp. 830-838
[175.]
L.A. Aaltonen, R. Salovaara, P. Kristo, F. Canzian, A. Hemminki, P. Peltomaki, et al.
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease.
N Engl J Med, 338 (1998), pp. 1.481-1.487
[176.]
J.R. Jass, T.C. Smyrk, S.M. Stewart, M.R. Lane, S.J. Lanspa, H.T. Lynch.
Pathology of hereditary non-polyposis colorectal cancer.
Anticancer Res, 14 (1994), pp. 1.631-1.634
[177.]
H.F. Vasen, J.P. Mecklin, P.M. Khan, H.T. Lynch.
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC).
Dis Colon Rectum, 34 (1991), pp. 424-425
[178.]
H.F. Vasen, P. Watson, J.P. Mecklin, H.T. Lynch.
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.
Gastroenterology, 116 (1999), pp. 1.453-1.456
[179.]
B. Liu, R. Parsons, N. Papadopoulos, N.C. Nicolaides, H.T. Lynch, P. Watson, et al.
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients.
Nat Med, 2 (1996), pp. 169-174
[180.]
J.R. Jass, V. Pokos, J.L. Arnold, D.S. Cottier, P. Jeevaratnam, NS Van de Water, et al.
Colorectal neoplasms detected colonoscopically in at-risk members of colorectal cancer families stratified by the demonstration of DNA microsatellite instability.
J Mol Med, 74 (1996), pp. 547-551
[181.]
J.R. Jass, D.S. Cottier, P. Jeevaratnam, V. Pokos, K.M. Holdaway, M.L. Bowden, et al.
Diagnostic use of microsatellite instability in hereditary non-polyposis colorectal cancer.
Lancet, 346 (1995), pp. 1.200-1.201
[182.]
C.M. Lewis, S.L. Neuhausen, D. Daley, F.J. Black, J. Swensen, R.W. Burt, et al.
Genetic heterogeneity and unmapped genes for colorectal cancer.
Cancer Res, 56 (1996), pp. 1.382-1.388
[183.]
B. Liu, S.M. Farrington, G.M. Petersen, S.R. Hamilton, R. Parsons, N. Papadopoulos, et al.
Genetic instability occurs in the majority of young patients with colorectal cancer.
Nat Med, 1 (1995), pp. 348-352
[184.]
N.E. Beck, I.P. Tomlinson, T. Homfray, S.V. Hodgson, C.J. Harocopos, W.F. Bodmer.
Genetic testing is important in families with a history suggestive of hereditary non-polyposis colorectal cancer even if the Amsterdam criteria are not fulfilled.
Br J Surg, 84 (1997), pp. 233-237
[185.]
M.A. Rodriguez-Bigas, C.R. Boland, S.R. Hamilton, D.E. Henson, J.R. Jass, P.M. Khan, et al.
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines.
J Natl Cancer Inst, 89 (1997), pp. 1.758-1.762
[186.]
S.D. Ramsey, L. Clarke, R. Etzioni, M. Higashi, K. Berry, N. Urban.
Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer.
Ann Intern Med, 135 (2001), pp. 577-588
[187.]
H.J. Jarvinen, M. Aarnio, H. Mustonen, K. Aktan-Collan, L.A. Aaltonen, P. Peltomaki, et al.
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer.
Gastroenterology, 118 (2000), pp. 829-834
[188.]
H.F. Vasen, F.M. Nagengast, P.M. Khan.
Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome).
Lancet, 345 (1995), pp. 1.183-1.184
[189.]
P. Lynch.
If aggressive surveillance in hereditary nonpolyposis colorectal cancer is now state of the art are there any challenges left?.
Gastroenterology, 118 (2000), pp. 969-971
[190.]
H.F. Vasen, M. van Ballegooijen, E. Buskens, J.K. Kleibeuker, B.G. Taal, G. Griffioen, et al.
A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers.
Cancer, 82 (1998), pp. 1.632-1.637
[191.]
M. Aarnio, R. Sankila, E. Pukkala, R. Salovaara, L.A. Aaltonen, A de la Chapelle, et al.
Cancer risk in mutation carriers of DNAmismatch-repair genes.
Int J Cancer, 81 (1999), pp. 214-218
[192.]
W. Burke, G. Petersen, P. Lynch, J. Botkin, M. Daly, J. Garber, et al.
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium.
JAMA, 277 (1997), pp. 915-919
[193.]
L. Renkonen-Sinisalo, P. Sipponen, M. Aarnio, R. Julkunen, L.A. Aaltonen, S. Sarna, et al.
No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer.
Scand J Gastroenterol, 37 (2002), pp. 574-577
[194.]
I. Dove-Edwin, D. Boks, S. Goff, G.G. Kenter, R. Carpenter, H.F. Vasen, et al.
The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma.
Cancer, 94 (2002), pp. 1.708-1.712
[195.]
H.F. Vasen, J.T. Wijnen, F.H. Menko, J.H. Kleibeuker, B.G. Taal, G. Griffioen, et al.
Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.
Gastroenterology, 110 (1996), pp. 1.020-1.027
[196.]
H.F. Vasen, A. Stormorken, F.H. Menko, F.M. Nagengast, J.H. Kleibeuker, G. Griffioen, et al.
MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
J Clin Oncol, 19 (2001), pp. 4.074-4.080
[197.]
H.T. Lynch, T. Smyrk, J.F. Lynch.
Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome).
Int J Cancer, 69 (1996), pp. 38-43
[198.]
M.A. Rodriguez-Bigas, H.F. Vasen, J. Pekka-Mecklin, T. Myrhoj, P. Rozen, L. Bertario, et al.
Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC.
Ann Surg, 225 (1997), pp. 202-207
[199.]
C.S. Fuchs, E.L. Giovannucci, G.A. Colditz, D.J. Hunter, F.E. Speizer, W.C. Willett.
A prospective study of family history and the risk of colorectal cancer.
N Engl J Med, 331 (1994), pp. 1.669-1.674
[200.]
D.J. St John, F.T. McDermott, J.L. Hopper, E.A. Debney, W.R. Johnson, E.S. Hughes.
Cancer risk in relatives of patients with common colorectal cancer.
Ann Intern Med, 118 (1993), pp. 785-790
[201.]
S.J. Winawer, A.G. Zauber, H. Gerdes, M.J. O'Brien, L.S. Gottlieb, S.S. Sternberg, et al.
Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup.
N Engl J Med, 334 (1996), pp. 82-87
[202.]
H. Ahsan, A.I. Neugut, G.C. Garbowski, J.S. Jacobson, K.A. Forde, M.R. Treat, et al.
Family history of colorectal adenomatous polyps and increased risk for colorectal cancer.
Ann Intern Med, 128 (1998), pp. 900-905
[203.]
L.E. Johns, R.S. Houlston.
A systematic review and meta-analysis of familial colorectal cancer risk.
Am J Gastroenterol, 96 (2001), pp. 2.992-3.003
[204.]
M.L. Slattery, R.A. Kerber.
Family history of cancer and colon cancer risk: the Utah Population Database.
J Natl Cancer Inst, 86 (1994), pp. 1.618-1.626
[205.]
P.S. Schoenfeld, R. Keith Fincher.
group ftMCCST. Colonoscopic surveillance of patients with a family history of colon cancer and a history of normal colonoscopy: is a five-year interval between colonoscopies appropriate?.
Clin Gastroenterol Hepatol, 1 (2003), pp. 310-314
[206.]
T. Byers, B. Levin, D. Rothenberger, G.D. Dodd, R.A. Smith.
American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997 American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer.
CA Cancer J Clin, 47 (1997), pp. 154-160
[207.]
S. Anwar, J. White, C. Hall, W.E. Farrell, M. Deakin, J.B. Elder.
Sporadic colorectal polyps: management options and guidelines.
Scand J Gastroenterol, 34 (1999), pp. 4-11
[208.]
J.H. Bond.
Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology.
Am J Gastroenterol, 95 (2000), pp. 3.053-3.063
[209.]
M.J. O'Brien, S.J. Winawer, A.G. Zauber, L.S. Gottlieb, S.S. Sternberg, B. Diaz, et al.
The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas.
Gastroenterology, 98 (1990), pp. 371-379
[210.]
E.M. Ward, H.C. Wolfsen.
Review article: the non-inherited gastrointestinal polyposis syndromes.
Aliment Pharmacol Ther, 16 (2002), pp. 333-342
[211.]
F.M. Giardiello, J.D. Brensinger, A.C. Tersmette, S.N. Goodman, G.M. Petersen, S.V. Booker, et al.
Very high risk of cancer in familial Peutz-Jeghers syndrome.
Gastroenterology, 119 (2000), pp. 1.447-1.453
[212.]
E.R. Fearon, B. Vogelstein.
A genetic model for colorectal tumorigenesis.
Cell, 61 (1990), pp. 759-767
[213.]
W.S. Atkin, B.P. Saunders.
Surveillance guidelines after removal of colorectal adenomatous polyps.
Gut, 51 (2002), pp. V6-V9
[214.]
S.J. Winawer, A.G. Zauber, M.N. Ho, M.J. O'Brien, L.S. Gottlieb, S.S. Sternberg, et al.
Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup.
N Engl J Med, 329 (1993), pp. 1.977-1.981
[215.]
A. Leslie, F.A. Carey, N.R. Pratt, R.J. Steele.
The colorectal adenoma-carcinoma sequence.
Br J Surg, 89 (2002), pp. 845-860
[216.]
M. Gschwantler, S. Kriwanek, E. Langner, B. Goritzer, C. Schrutka-Kolbl, E. Brownstone, et al.
High-grade dysplasia and invasive carcinoma in colorectal adenomas: a multivariate analysis of the impact of adenoma and patient characteristics.
Eur J Gastroenterol Hepatol, 14 (2002), pp. 183-188
[217.]
D.K. Rex, J.H. Bond, S. Winawer, T.R. Levin, R.W. Burt, D.A. Johnson, et al.
Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer.
Am J Gastroenterol, 97 (2002), pp. 1.296-1.308
[218.]
Workshop PitP. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon.
Gastrointest Endosc, 58 (2003), pp. s3-s43
[219.]
S. Dave, S. Hui, K. Kroenke, T.F. Imperiale.
Is the distal hyperplastic polyp a marker for proximal neoplasia?.
J Gen Intern Med, 18 (2003), pp. 128-137
[220.]
O.D. Jorgensen, O. Kronborg, C. Fenger.
The Funen Adenoma Follow-Up Study. Characteristics of patients and initial adenomas in relation to severe dysplasia.
Scand J Gastroenterol, 28 (1993), pp. 239-243
[221.]
R.U. van Stolk, G.J. Beck, J.A. Baron, R. Haile, R. Summers.
Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The Polyp Prevention Study Group.
Gastroenterology, 115 (1998), pp. 13-18
[222.]
M.E. Martinez, R. Sampliner, J.R. Marshall, A.K. Bhattacharyya, M.E. Reid, D.S. Alberts.
Adenoma characteristics as risk factors for recurrence of advanced adenomas.
Gastroenterology, 120 (2001), pp. 1.077-1.083
[223.]
W.S. Atkin, B.C. Morson, J. Cuzick.
Long-term risk of colorectal cancer after excision of rectosigmoid adenomas.
N Engl J Med, 326 (1992), pp. 658-662
[224.]
O.D. Jorgensen, O. Kronborg, C. Fenger.
A randomized surveillance study of patients with pedunculated and small sessile tubular and tubulovillous adenomas. The Funen Adenoma Follow-up Study.
Scand J Gastroenterol, 30 (1995), pp. 686-692
[225.]
J.N. Lund, J.H. Scholefield, M.J. Grainge, S.J. Smith, C. Mangham, N.C. Armitage, et al.
Risks, costs, and compliance limit colorectal adenoma surveillance: lessons from a randomised trial.
Gut, 49 (2001), pp. 91-96
[226.]
D.F. Ransohoff, C.A. Lang, H.S. Kuo.
Colonoscopic surveillance after polypectomy: considerations of cost effectiveness.
Ann Intern Med, 114 (1991), pp. 177-182
[227.]
G.E. McKeown-Eyssen, E. Bright-See, W.R. Bruce, V. Jazmaji, L.B. Cohen, S.C. Pappas, et al.
A randomized trial of a low fat high fibre diet in the recurrence of colorectal polyps. Toronto Polyp Prevention Group.
J Clin Epidemiol, 47 (1994), pp. 525-536
[228.]
A. Schatzkin, E. Lanza, D. Corle, P. Lance, F. Iber, B. Caan, et al.
Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group.
N Engl J Med, 342 (2000), pp. 1.149-1.155
[229.]
D.S. Alberts, M.E. Martinez, D.J. Roe, J.M. Guillen-Rodriguez, J.R. Marshall, JB van Leeuwen, et al.
Lack of effect of a highfiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network.
N Engl J Med, 342 (2000), pp. 1.156-1.162
[230.]
M.V. Grau, J.A. Baron, R.S. Sandler, R.W. Haile, M.L. Beach, T.R. Church, D. Vitamin, et al.
calcium supplementation, and colorectal adenomas: results of a randomized trial.
J Natl Cancer Inst, 95 (2003), pp. 1.765-1.771
[231.]
N. Malila, J. Virtamo, M. Virtanen, D. Albanes, J.A. Tangrea, J.K. Huttunen.
The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers.
Cancer Epidemiol Biomarkers Prev, 8 (1999), pp. 489-493
[232.]
J.A. Eaden, K.R. Abrams, J.F. Mayberry.
The risk of colorectal cancer in ulcerative colitis: a meta-analysis.
Gut, 48 (2001), pp. 526-535
[233.]
T.A. Ullman.
Dysplasia and colorectal cancer in Crohn's disease.
J Clin Gastroenterol, 36 (2003), pp. S75-S78
[234.]
R. Sharan, R.E. Schoen.
Cancer in inflammatory bowel disease. An evidence-based analysis and guide for physicians and patients.
Gastroenterol Clin North Am, 31 (2002), pp. 237-254
[235.]
A. Ekbom, C. Helmick, M. Zack, H.O. Adami.
Ulcerative colitis and colorectal cancer. A population-based study.
N Engl J Med, 323 (1990), pp. 1.228-1.233
[236.]
R.M. Soetikno, O.S. Lin, P.A. Heidenreich, H.S. Young, M.O. Blackstone.
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a metaanalysis.
Gastrointest Endosc, 56 (2002), pp. 48-54
[237.]
J. Askling, P.W. Dickman, P. Karlen, O. Brostrom, A. Lapidus, R. Lofberg, et al.
Family history as a risk factor for colorectal cancer in inflammatory bowel disease.
Gastroenterology, 120 (2001), pp. 1.356-1.362
[238.]
F. Delco, A. Sonnenberg.
The unsolved problem of surveillance for colorectal cancer in ulcerative colitis.
Can J Gastroenterol, 13 (1999), pp. 655-660
[239.]
E.V. Loftus Jr.
Does monitoring prevent cancer in inflammatory bowel disease?.
J Clin Gastroenterol, 36 (2003), pp. S79-S83
[240.]
J. Eaden, K. Abrams, A. Ekbom, E. Jackson, J. Mayberry.
Colorectal cancer prevention in ulcerative colitis: a case-control study.
Aliment Pharmacol Ther, 14 (2000), pp. 145-153
[241.]
P. Karlen, D. Kornfeld, O. Brostrom, R. Lofberg, P.G. Persson, A. Ekbom.
Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study.
Gut, 42 (1998), pp. 711-714
[242.]
P.M. Choi, F.W. Nugent, J.r. Schoetz DJ, M.L. Silverman, R.C. Haggitt.
Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis.
Gastroenterology, 105 (1993), pp. 418-424
[243.]
J.A. Eaden, J.F. Mayberry.
Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.
Gut, 51 (2002), pp. V10-V12
[244.]
J.M. Inadomi.
Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis.
Scand J Gastroenterol, (2003), pp. 17-21
[245.]
E.V. Loftus Jr, H.I. Aguilar, W.J. Sandborn, W.J. Tremaine, R.A. Krom, A.R. Zinsmeister, et al.
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation.
Hepatology, 27 (1998), pp. 685-690
[246.]
R. Kiesslich, J. Fritsch, M. Holtmann, H.H. Koehler, M. Stolte, S. Kanzler, et al.
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.
Gastroenterology, 124 (2003), pp. 880-888
[247.]
T. Matsumoto, S. Nakamura, Y. Jo, T. Yao, M. Iida.
Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis.
Am J Gastroenterol, 98 (2003), pp. 1.827-1.833
[248.]
D. Provenzale, J.B. Wong, J.E. Onken, J. Lipscomb.
Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis.
Am J Gastroenterol, 93 (1998), pp. 872-880
[249.]
F. Delco, A. Sonnenberg.
A decision analysis of surveillance for colorectal cancer in ulcerative colitis.
Gut, 46 (2000), pp. 500-506
[250.]
D. Provenzale, J. Onken.
Surveillance issues in inflammatory bowel disease: ulcerative colitis.
J Clin Gastroenterol, 32 (2001), pp. 99-105
[251.]
R. Odze.
Diagnostic problems and advances in inflammatory bowel disease.
Mod Pathol, 16 (2003), pp. 347-358
[252.]
J.R. Goldblum.
The histologic diagnosis of dysplasia, dysplasiaassociated lesion or mass, and adenoma: a pathologist's perspective.
J Clin Gastroenterol, 36 (2003), pp. S63-S69
[253.]
S. Friedman, R.D. Odze, F.A. Farraye.
Management of neoplastic polyps in inflammatory bowel disease.
Inflamm Bowel Dis, 9 (2003), pp. 260-266
[254.]
C.N. Bernstein, F. Shanahan, W.M. Weinstein.
Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?.
Lancet, 343 (1994), pp. 71-74
[255.]
W.R. Connell, J.E. Lennard-Jones, C.B. Williams, I.C. Talbot, A.B. Price, K.H. Wilkinson.
Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis.
Gastroenterology, 107 (1994), pp. 934-944
[256.]
S.R. Gorfine, J.J. Bauer, M.T. Harris, I. Kreel.
Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted?.
Dis Colon Rectum, 43 (2000), pp. 1.575-1.581
[257.]
T.A. Ullman, E.V. Loftus Jr, S. Kakar, L.J. Burgart, W.J. Sandborn, W.J. Tremaine.
The fate of low grade dysplasia in ulcerative colitis.
Am J Gastroenterol, 97 (2002), pp. 922-927
[258.]
T. Ullman, V. Croog, N. Harpaz, D. Sachar, S. Itzkowitz.
Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis.
Gastroenterology, 125 (2003), pp. 1.311-1.319
[259.]
C.H. Lim, M.F. Dixon, A. Vail, D. Forman, D.A. Lynch, A.T. Axon.
Ten year follow up of ulcerative colitis patients with and without low grade dysplasia.
Gut, 52 (2003), pp. 1.127-1.132
[260.]
P. Rubin, S. Friedman, N. Harpaz, E. Goldstein, J. Weiser, J. Schiller, et al.
Colonoscopic polypectomy in chronic colitis: Conservative management after endoscopic resection of dysplastic polyps.
Gastroenterology, 117 (1999), pp. 1.295-1.300
[261.]
C. Torres, D. Antonioli, R.D. Odze.
Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up study of 89 polyps from 59 patients.
Am J Surg Pathol, 22 (1998), pp. 275-284
[262.]
M. Engelsgjerd, F.A. Farraye, R.D. Odze.
Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis.
Gastroenterology, 117 (1999), pp. 1.288-1.294
[263.]
R.H. Riddell.
Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems.
Am J Gastroenterol, 91 (1996), pp. 864-872
[264.]
A. Chawla, T.A. Judge, G.R. Lichtenstein.
Evaluation of polypoid lesions in inflammatory bowel disease.
Gastrointest Endosc Clin N Am, 12 (2002), pp. 525-534
[265.]
Y. Ziv, V.W. Fazio, M.T. Sirimarco, I.C. Lavery, J.R. Goldblum, R.E. Petras.
Incidence, risk factors, and treatment of dysplasia in the anal transitional zone after ileal pouch-anal anastomosis.
Dis Colon Rectum, 37 (1994), pp. 1.281-1.285
[266.]
F.H. Remzi, V.W. Fazio, C.P. Delaney, M. Preen, A. Ormsby, J. Bast, et al.
Dysplasia of the anal transitional zone after ileal pouchanal anastomosis: results of prospective evaluation after a minimum of ten years.
Dis Colon Rectum, 46 (2003), pp. 6-13
[267.]
D. Pinczowski, A. Ekbom, J. Baron, J. Yuen, H.O. Adami.
Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.
Gastroenterology, 107 (1994), pp. 117-120
[268.]
G.A. Moody, V. Jayanthi, C.S. Probert, H. Mac Kay, J.F. Mayberry.
Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 1.179-1.183
[269.]
B.U. Lindberg, U. Broome, B. Persson.
Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study.
Dis Colon Rectum, 44 (2001), pp. 77-85
[270.]
B.A. Lashner, P.A. Heidenreich, G.L. Su, S.V. Kane, S.B. Hanauer.
Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study.
Gastroenterology, 97 (1989), pp. 255-259
[271.]
B.A. Lashner.
Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis.
J Cancer Res Clin Oncol, 119 (1993), pp. 549-554
[272.]
B.A. Lashner, K.S. Provencher, D.L. Seidner, A. Knesebeck, A. Brzezinski.
The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis.
Gastroenterology, 112 (1997), pp. 29-32
[273.]
D.S. Pardi, E.V. Loftus Jr, W.K. Kremers, J. Keach, K.D. Lindor.
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
Gastroenterology, 124 (2003), pp. 889-893
[274.]
M. Pignone, M.K. Campbell, C. Carr, C. Phillips.
Meta-analysis of dietary restriction during fecal occult blood testing.
Eff Clin Pract, 4 (2001), pp. 150-156
[275.]
G.P. Young, D.J. St John, S.J. Winawer, P. Rozen.
Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO and OMED report.
Am J Gastroenterol, 97 (2002), pp. 2.499-2.507
[276.]
S.M. Powell, G.M. Petersen, A.J. Krush, S. Booker, J. Jen, F.M. Giardiello, et al.
Molecular diagnosis of familial adenomatous polyposis.
N Engl J Med, 329 (1993), pp. 1.982-1.987
[277.]
G. Li, K. Tamura, Y. Yamamoto, H. Sashio, J. Utsunomiya, T. Yamamura, et al.
Molecular and clinical study of familial adenomatous polyposis for genetic testing and management.
J Exp Clin Cancer Res, 18 (1999), pp. 519-529
[278.]
H. Nagase, Y. Miyoshi, A. Horii, T. Aoki, M. Ogawa, J. Utsunomiya, et al.
Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients.
Cancer Res, 52 (1992), pp. 4.055-4.057
[279.]
L. Bertario, A. Russo, P. Sala, L. Varesco, M. Giarola, P. Mondini, et al.
Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis.
J Clin Oncol, 21 (2003), pp. 1.698-1.707
[280.]
C.R. Boland, S.N. Thibodeau, S.R. Hamilton, D. Sidransky, J.R. Eshleman, R.W. Burt, et al.
A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.
Cancer Res, 58 (1998), pp. 5.248-5.257
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
